

## Section Appendix 6-5: Sample ART Drug Resistance Report



### ViroSeq™ HIV-1 Antiretroviral Drug Resistance Report

Patient ID	208-0000xxx	Testing Laboratory	MTN Virology CORE Lab 470
Patient Name Last	-----	Lab Director	Urvi Parikh PhD Assoc Dir
Patient Name First MI	-----	Department ID	
Accession Number	-----	Mailstop	
Patient Gender	Female	Street Address1	S804 Scaife Hall
Patient Birthdate & Age		Street Address2	3550 Terrace St
Report Generated By	admin	City	Pittsburgh
Report Date & Time	15 Apr 2010, 03:08:44 PM, EDT	State/Province	PA
Ordering Physician	-----	Postal Code	15216
Institution	Durban	Country	USA
Date Drawn	17 Mar 2010	Telephone/Fax	Ph: 412-648-3103 Fax: 412-648-8521
Assay Operator	Krista Eskay	E-mail	ump3@pitt.edu
Field1	MTN-009	Web Site	www.mtnstopshiv.org
Field2	-----		

Drug Class	Drug	Evidence of Resistance
<b>NRTI</b>	<b>EPIVIR®</b> (lamivudine, 3TC)	None
	<b>EMTRIVA®</b> (emtricitabine, FTC)	None
	<b>RETROVIR®</b> (zidovudine, AZT)	None
	<b>VIDEX®</b> (didanosine, ddI)	None
	<b>ZERIT®</b> (stavudine, d4T)	None
	<b>ZIAGEN®</b> (abacavir, ABC)	None
	<b>VIREAD®</b> (tenofovir, TDF)	None
<b>NNRTI</b>	<b>RESCRIPTOR®</b> (delavirdine, DLV)	Resistance
	<b>SUSTIVA®</b> (efavirenz, EFV)	Resistance
	<b>VIRAMUNE®</b> (nevirapine, NVP)	Resistance
<b>PI<sup>+</sup></b>	<b>INTELENCE™</b> (etravirine, ETR)	None
	<b>AGENERASE®</b> (amprenavir, APV)	None
	<b>LEXIVA®</b> (fosamprenavir, FOS)	None
	<b>CRIXIVAN®</b> (indinavir, IDV)	None
	<b>FORTOVASE® / INVIRASE®</b> (saquinavir, SQV)	None
	<b>KALETRA®</b> (lopinavir + ritonavir, LPV)	None
	<b>PREZISTA®</b> (darunavir, DRV)	None
	<b>VIRACEPT®</b> (nelfinavir, NFV)	None
	<b>REYATAZ®</b> (atazanavir, ATV)	None
<b>APTIVUS®</b> (tipranavir, TPV)	None	

Drug Class	Drug Resistance Mutations Identified
<b>NRTI</b>	
<b>NNRTI</b>	K103N
<b>PI</b>	

\* NOTE: At least one mutation used to determine Evidence of Resistance for this drug has not been fully validated.  
 \*\* NOTE: At least one mutation used to determine Evidence of Resistance for this drug has not been clinically verified.  
 \*\*\* NOTE: For at least one mutation used to evaluate Evidence of Resistance for this drug, both notes above apply.  
 + Evidence of Resistance for Protease Inhibitors estimates response to ritonavir-boosted regimens. Refer to section titled "Notes on Evidence of Resistance".

#### Review & Release of Results

Signature / Date: \_\_\_\_\_ Name(Print) / Title: \_\_\_\_\_  
 Notes: \_\_\_\_\_

FOR IN VITRO DIAGNOSTIC USE

Project ID: C:\Documents and Settings\parikh\Desktop\009 TRAINING\GEN018DR\_05A\GEN018DR\_05A